R. T. Penson

Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer

M. William Audeh, R. T. Penson, Michael Friedländer et al. · Journal of Clinical Oncology · 2009 · 107 citations

Phase Ii Trial, Medicine, Cancer Management +15

Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study

Eric Pujade‐Lauraine, J.A. Ledermann, R. T. Penson et al. · Gynecologic Oncology · 2017 · 45 citations

Progression-free Survival, Medicine, Cancer Management +7

A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer.

R. T. Penson, Charles J. Whalen, Brian Lasonde et al. · Journal of Clinical Oncology · 2011 · 33 citations

Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer

Ursula A. Matulonis, Suzanne Berlin, Carolyn Krasner et al. · Journal of Clinical Oncology · 2008 · 33 citations

Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors

R. T. Penson, S A Cannistra, Michael V. Seiden et al. · Journal of Clinical Oncology · 2006 · 22 citations

First Line Chemotherapy, Consolidation Bevacizumab, Medicine +14